Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years’-follow-up results from a randomised phase III trial

Reck, Martin; Pawel, Joachim von; Macha, H.-N.; Kaukel, E.; Deppermann, Karl-Matthias; Bonnet, R.; Ulm, Kurt; Hessler, Sybill; Gatzemeier, U.

doi:10.1016/j.lungcan.2006.04.001

Cited by 23 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 27 publications included in this review reported results from interventional clinical trials assessing HRQoL as an endpoint (n = 18); 11 were randomized but not controlled (Thatcher et al, 2005;Eckardt et al, 2006;Reck et al, 2006Reck et al, , 2012Hermes et al, 2008;Lee et al, 2009;Le Pechoux et al, 2011;Nagel et al, 2011;Wolfson et al, 2011;Satouchi et al, 2014;Sekine et al, 2014) (see Table 2), four were randomized controlled trials (RCTs) (Giaccone et al, 2005;O'Brien et al, 2006;Bottomley et al, 2008;Slotman et al, 2009) (see Table 3) and three were nonrandomized interventional studies (Fennell et al, 2007;Araujo et al, 2009;Eckardt et al, 2009) (see Table 4). The remaining publications were real world (n = 7) (Jatoi et al, 2005;Chen et al, 2007Chen et al, , 2008Chen et al, , 2012Rolke et al, 2008;Kohli et al, 2010;Nakahara et al, 2015) (see Table 5) and mixed-methods studies (n = 2) (Westerman et al, 2007(Westerman et al, , 2008) (see Table 6).…”

Section: Resultsmentioning

confidence: 99%

“…Real world EORTC QLQ-C30 data could be drawn from one study only, reporting a mean score of 49.6 (Rolke et al, 2008). This score falls within the range of clinical trial EORTC QLQ-C30 baseline scores (Reck et al, 2006;Bottomley et al, 2008;Hermes et al, 2008;Lee et al, 2009;Slotman et al, 2009), indicating no difference in scores between the population types.…”

Section: Global Hrqolmentioning

confidence: 95%

“…In the LCSS, the second most frequently used PRO to measure the concept (n = 4, 19%, Jatoi et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009Chen et al, 2012), global QoL is assessed via a single item. Most chemotherapy naïve LD and ED SCLC patients had EORTC QLQ-C30 Global health/quality of life mean baseline scores ranged between 44.7 and 55.4 (Reck et al, 2006;Hermes et al, 2008;Rolke et al, 2008;Lee et al, 2009). One study however reported baseline scores that were over 10 points higher, at 66 points.…”

Section: Global Hrqolmentioning

confidence: 99%

“…Global HRQoL (Giaccone et al, 2005;Jatoi et al, 2005;Thatcher et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009O'Brien et al, 2006;Reck et al, 2006Reck et al, , 2012Fennell et al, 2007;Bottomley et al, 2008;Hermes et al, 2008;Rolke et al, 2008;Westerman et al, 2008;Araujo et al, 2009;Lee et al, 2009;Slotman et al, 2009;Le Pechoux et al, 2011;Nagel et al, 2011;Wolfson et al, 2011;Chen et al, 2012;Sekine et al, 2014) was most frequently measured using two items (overall health and overall QoL) in the EORTC QLQ-C30 (n = 13, 62%). In the LCSS, the second most frequently used PRO to measure the concept (n = 4, 19%, Jatoi et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009Chen et al, 2012), global QoL is assessed via a single item.…”

Section: Global Hrqolmentioning

confidence: 99%

See 3 more Smart Citations

The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature

et al. 2016

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Global Hrqolmentioning

confidence: 95%

Section: Global Hrqolmentioning

confidence: 99%

Section: Global Hrqolmentioning

confidence: 99%

See 2 more Smart Citations

The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature

et al. 2016

View full text Add to dashboard Cite

“…A significant survival benefit was also observed in the subgroup of patients with stage IV disease (HR 1.27, 95% CI, 1.00-1.60; p5 0.047). In addition, patients in the TEC arm reported less grade 3/4 toxicity, and showed improvements in several relevant QoL parameters including global overall QoL and physical functioning [70].…”

Section: Newer Chemotherapeutic Agentsmentioning

confidence: 96%

Update on small cell lung cancer management

Huber¹,

Tufman²

2012

breathe

View full text Add to dashboard Cite

SummarySmall cell lung cancers (SCLCs) account for ,15-20% of all lung cancers. Because SCLC is almost always associated with long-term tobacco smoking, abstinence from smoking and smoking cessation are crucial for primary prevention. Because symptoms are generally unspecific, the disease is often diagnosed late, with 70% of patients already in stage IIIb or IV at the time of diagnosis. Early detection of SCLC through screening is under investigation. Chemotherapy, generally a platinum-based combination, is the mainstay of therapy and is generally combined with radiation in the first-line treatment of tumours up to stage IIIb. Surgery has a place in the diagnosis and therapy of stage I SCLC, but plays no key role in advanced cancer. In patients who respond to first-line therapy, prophylactic cranial irradiation can prevent brain metastases and improve overall survival. Although the initial response to treatment is usually good, SCLC tends to relapse quickly. This makes second-line therapy quite important. Topotecan is the most studied and widely used agent in second-line therapy; however, newer agents, including biological therapies, are under study. Statement of interestNone declared.HERMES syllabus links: module B. 2. 1

show abstract

Simultaneous LC‐MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self‐microemulsifying drug‐delivery systems

Zhao

et al. 2018

Biomedical Chromatography

View full text Add to dashboard Cite

In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to simultaneously determine the anticancer drugs etoposide and paclitaxel in mouse plasma and tissues including liver, kidney, lung, heart, spleen and brain. The analytes were extracted from the matrices of interest by liquid-liquid extraction using methyl tert-butyl ether-dichloromethane (1:1, v/v). Chromatographic separation was achieved on an Ultimate XB-C column (100 × 2.1 mm, 3 μm) at 40°C and the total run time was 4 min under a gradient elution. Ionization was conducted using electrospray ionization in the positive mode. Stable isotope etoposide-d3 and docetaxel were used as the internal standards. The lower limit of quantitation (LLOQ) of etoposide was 1 ng/g tissue for all tissues and 0.5 ng/mL for plasma. The LLOQ of paclitaxel was 0.4 ng/g tissue and 0.2 ng/mL for all tissues and plasma, respectively. The coefficients of correlation for all of the analytes in the tissues and plasma were >0.99. Both intra- and inter-day accuracy and precision were satisfactory. This method was successfully applied to measure plasma and tissue drug concentrations in mice treated with etoposide and paclitaxel-loaded self-microemulsifying drug-delivery systems.

show abstract

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years’-follow-up results from a randomised phase III trial

Cited by 23 publications

References 34 publications

The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature

The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature

Update on small cell lung cancer management

Simultaneous LC‐MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self‐microemulsifying drug‐delivery systems

Contact Info

Product

Resources

About